Unicycive Therapeutics appoints Meredith Manning to board, names her nominating committee chair
Bitget2026/10/01 11:05- Unicycive Therapeutics appointed Meredith Manning to its board.
- Manning joined the audit, compensation, nominating and corporate governance committees. She will chair the nominating and corporate governance committee.
- She was chief commercial officer at Soleno Therapeutics from 2024 until its 2026 acquisition by Neurocrine Biosciences.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Temasek Chief Investment Officer warns: AI trading reversal is the biggest market risk, turbulence may occur in 2027
Temasek's CIO stated that AI-driven trading reversals represent the greatest market risk, with possible turbulence in 2027; however, he remains optimistic in the long term and plans to raise public AI exposure to 70%—75%.
Intel Confirms Advancement of Musk's "Terafab" Chip Plan Amid Stock Price Pressure
Intel CEO Pat Gelsinger stated that the company will continue to participate in Elon Musk's Terafab project. Previously, Musk revealed ongoing discussions with TSMC about potential collaboration, which raised market concerns over Intel's position in the project. As a result, Intel's stock price once dropped by 3.9%.
Gold Price Forecast: XAU/USD retraces gains and nears two-month lows at $4,104
Crypto prices
More
